VWR Corp (VWR) Given Average Recommendation of “Hold” by Brokerages
Shares of VWR Corp (NASDAQ:VWR) have been given an average recommendation of “Hold” by the seven research firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $31.67.
Several research analysts have weighed in on VWR shares. Zacks Investment Research upgraded VWR from a “hold” rating to a “buy” rating and set a $37.00 price target for the company in a research note on Tuesday, September 12th. BidaskClub downgraded VWR from a “sell” rating to a “strong sell” rating in a research note on Saturday, September 2nd. Finally, ValuEngine upgraded VWR from a “hold” rating to a “buy” rating in a research note on Tuesday, November 7th.
Institutional investors and hedge funds have recently modified their holdings of the company. SG Americas Securities LLC increased its stake in VWR by 1,089.9% in the third quarter. SG Americas Securities LLC now owns 191,283 shares of the medical research company’s stock worth $6,333,000 after purchasing an additional 175,208 shares during the period. Aperio Group LLC increased its stake in VWR by 84.4% in the second quarter. Aperio Group LLC now owns 49,608 shares of the medical research company’s stock worth $1,638,000 after purchasing an additional 22,712 shares during the period. Schroder Investment Management Group increased its stake in VWR by 0.6% in the third quarter. Schroder Investment Management Group now owns 2,987,927 shares of the medical research company’s stock worth $98,871,000 after purchasing an additional 18,316 shares during the period. Crossmark Global Holdings Inc. purchased a new stake in VWR in the third quarter worth $318,000. Finally, Colony Group LLC increased its stake in VWR by 6.5% in the second quarter. Colony Group LLC now owns 144,191 shares of the medical research company’s stock worth $4,760,000 after purchasing an additional 8,835 shares during the period. 96.66% of the stock is currently owned by institutional investors and hedge funds.
VWR (NASDAQ:VWR) last posted its quarterly earnings results on Tuesday, November 7th. The medical research company reported $0.54 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.46 by $0.08. VWR had a return on equity of 11.79% and a net margin of 4.11%. The business had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.16 billion. During the same period in the prior year, the company posted $0.44 EPS. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. research analysts predict that VWR will post 1.85 earnings per share for the current year.
VWR Corporation is a provider of product and service solutions to laboratory and production customers. The Company offers a portfolio of branded and private label laboratory products, services and solutions to the life science, general research and applied markets. The Company operates in two segments: Americas and EMEA-APAC.
Receive News & Ratings for VWR Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VWR Corp and related companies with MarketBeat.com's FREE daily email newsletter.